Safety Of Narrow-band Ultraviolet B Research Articles

Efficacy and safety of Narrowband UVB in Chronic Plaque Psoriasis in Skin type IV and V

Efficacy and safety of Narrowband UVB in Chronic Plaque Psoriasis in Skin type IV and V

To Determine the Efficacy and Safety of Narrow Band UVB (NB-UVB) in Chronic Hand Eczema (CHE)

Aim: To d etermin e the safety and efficacy of narrow band ultravoilet B radiations in chronic hand eczema. Methods: 62 patients were enrolled from OPD of Dermatology Unit II, KEMU/ Mayo Hospital, Lahore. They weregiven phototherapy treatment through NB UVB local chamber, t hrice weekly (on fixed days) for a total of 12 weeks or until clearance. Patients were followed up fortnightly for further 1 month and final assessment was done at the end of one month. Physician’s Global Assessment (PGA) Score was used to assess the sever ity of eczema affecting the hands. Results The data was collected from 62 patients with 0% dropout. There was only one patient who had improvement <25%, 4(6.45%) had improvement 25 50%, 8(12.90%) had 51 75% improvement and 49(79.03%)cases had improvem ent >75%. Minimal side effects were seen which included erythema, photosensitivity, itching and pain. Conclusion : NB UBV is a safe as well as effective treatment option for chronic eczema of hands. Keywords : Chronic Hand Eczema, Narrow Band UVB, Physician’s Global Assessment Score.

A study to compare the efficacy and safety of narrow band-UVB alone as well as in combination with topical calcipotriol in patients with psoriasis vulgaris

Psoriasis is a complex disease that requires carefully designed therapy in order to achieve sustained remission. The disease can be effectively controlled by various therapeutic options, used alone or in combination. Phototherapy may be combined with topical or systemic agents to achieve higher clearance rates, longer disease free intervals and a lower carcinogenic risk. The combination of NB-UVB with calcipotriol increases the therapeutic efficacy of phototherapy as well as UVB reduces the irritation caused by calcipotriolThe chief purpose of this study was to compare the efficacy and safety of Narrow Band-UVB alone and in combination with topical calcipotriol in patients with psoriasis vulgaris.Patients with chronic plaque type psoriasis of 100 numbers involving less than 20% of body surface area were randomly allocated to any one of the following 2 groups. Group A- Narrow Band UVB phototherapy. & Group B- Narrow Band UVB with topical calcipotriol ointmentIn group A (NB-UVB), the mean baseline PASI score was 12.1 and the mean PASI score at the end of 12 weeks was 2.54. There was 79% reduction in PASI score at the end of 12 weeks. 31 patients showed good response and 13 patients showed more than 70% clearance.When NB-UVB group was compared with NB-UVB and calcipotriol combination group, there was a significant difference (p<0.05) in PASI scores at 4 weeks, 8 weeks and 12 weeks.Further studies with additional numbers of patients are essential to compare the efficacy and safety of Narrow Band-UVB alone as well as in combination with topical calcipotriol in patients with psoriasis vulgaris

What Is New in Narrow-Band Ultraviolet-B Therapy for Vitiligo?

Vitiligo is an acquired disorder of skin pigmentation that produces significant psychological impact especially in those with skin of color. Narrow-band ultraviolet B (NB-UVB) therapy, which was first used in vitiligo in 1997 by Westerhof and Nieuweboer-Krobotova, has emerged as one of the safest and most effective therapy for this dermatosis. The light source used for NB-UVB phototherapy is the TL-01 lamp, and the most common model of the NB-UVB phototherapy device is the upright in-office booth or chamber which has 24–48 such lamps. In recent years, there have been several advances in the understanding of the mechanism of action of NB-UVB and the use of combination treatments, many of which increase the efficacy of NB-UVB. In 2017, the Vitiligo Working Group made vital recommendations on the dosage, frequency, and safety of NB-UVB in vitiligo. Furthermore, home phototherapy devices are gaining popularity as they lead to an improved patient compliance. There is still need for large multicenter randomized controlled trials to assess benefits of home phototherapy in vitiligo and studies investigating additional benefits of phototherapy following surgical therapy.

Twenty‐year follow‐up using a postal survey of childhood vitiligo treated with narrowband ultraviolet B phototherapy

Vitiligo is a depigmenting skin disorder with an estimated prevalence of 1%.(1) Childhood-onset vitiligo occurs in approximately a third of all cases.(2) Early-onset childhood vitiligo tends to be a more extensive and progressive type of vitiligo.(3) Narrowband ultraviolet-B (NB-UVB) phototherapy is an effective treatment option in active vitiligo and leads to >75% repigmentation in 14-75% of childhood cases.(4,5) Unfortunately, no evidence is available whether this repigmentation is long-lasting. To date, no data are available on the long-term efficacy and safety of NB-UVB in childhood vitiligo. This article is protected by copyright. All rights reserved

Narrow-band ultraviolet B in childhood vitiligo: An open prospective uncontrolled study in 28 children of South India

Background: Management of vitiligo in children is difficult as therapeutic options are restricted when compared to that in adult patients. Selection of treatment should be careful in these patients with the aim to achieve best results with minimal side effects. Only few studies have been performed to evaluate the efficacy and safety of narrow-band ultraviolet B (NBUVB) therapy in children with vitiligo. Aims: The purpose of this study was to know the efficacy and safety of NBUVB in children with vitiligo of age group ranging from 3 to 16 years. Methods: Twenty-eight patients (12 males, 16 females), aged 3-16 years with vitiligo were included in the study between years 2011 and 2013 and were treated twice weekly with NBUVB. The starting dose was 150 mJ/cm 2 in children, with 20% dose increments at each subsequent visit given for a maximum period of 1-year and were followed-up for another 12 months for stability of repigmentation. Results: Analysis of our study showed that a majority of our cases, 22 (78.6%) had > 75% to complete repigmentation, about 4 (14.2%) achieved 26-75% moderate repigmentation and 2 (7.2%) had Conclusion: Our study proves that NBUVB therapy is safe and effective tool in the management of childhood vitiligo, with good stability of repigmentation.

Quantitative optical coherence tomography of skin lesions induced by different ultraviolet B sources

Ultraviolet B (UVB) has been widely used in dermatological phototherapy. Narrowband UVB (NB-UVB), with a peak at 311 nm, is considered to be more effective than broadband UVB (BB-UVB). However, the safety of NB-UVB is controversial. In this study, we first introduced optical coherence tomography (OCT), a novel, non-invasive in vivo imaging technology, to assess the effect of NB-UVB and BB-UVB on skin. Balb/c mice dorsal skin was exposed with increasing UVB doses (1MED, 3MEDs and 5MEDs), and then OCT images of the tissues were obtained by an OCT system with 1310 nm central wavelength. Quantitative parameters (skin thickness, disruption of the entrance signal and correlation coefficient) were extracted from the OCT images. The data indicated that NB-UVB-induced skin lesions were similar to that of BB-UVB at 1MED or 3MEDs UVB. However, the skin tissues exposed with 5MEDs NB-UVB suffered from more lesions than BB-UVB. Furthermore, the persistence of skin inflammation in 3MEDs NB-UVB-induced skin tissues was much longer than that of BB-UVB (P = 0.004). In conclusion, optimized treatment time and frequency as well as close clinical monitoring should be undertaken to reduce the latent risk of NB-UVB phototherapy.

Efficacy of narrowband UVB vs. PUVA in patients with early‐stage mycosis fungoides

Mycosis fungoides (MF) is a non-Hodgkin's T-cell lymphoma of the skin that often begins as limited patches and plaques with slow progression to systemic involvement. Narrowband ultraviolet (UV) B therapy has been proven to be an effective short-term treatment modality for clearing patch-stage MF. The effect of psoralen plus long-wave ultraviolet A (PUVA) in the treatment of patch- and plaque-type MF has also been thoroughly documented. The purpose of this study was to compare the efficacy and safety of narrowband UVB and PUVA in patients with early-stage MF. We analysed the response to treatment, relapse-free survival and irradiation dose in 114 patients with histologically confirmed early-stage MF (stage IA, IB and IIA). A total of 95 patients were treated with PUVA (83.3%) and 19 with narrowband UVB (16.7%). With PUVA, 59 patients (62.1%) had a complete response (CR), 24 (25.3%) had a partial response (PR) and 12 (12.6%) had a failed response. Narrowband UVB led to CR in 12 (68.4%) patients, PR in 5 (26.3%) patients and a failed response in 1 (5.3%) patient. There were no differences in terms of time to relapse between patients treated with PUVA and those treated with narrowband UVB (11.5 vs. 14.0 months respectively; P = 0.816). No major adverse reactions were attributed to the treatment. Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF.

Evaluation of narrow-band UVB phototherapy in 150 patients with vitiligo

Very few studies have been performed to evaluate the efficacy and safety of narrow-band ultraviolet B (NBUVB) therapy in Indian patients with vitiligo and are of small sample size. The purpose of this study is to know the efficacy and safety of NBUVB in 150 vitiligo patients of various age groups. One hundred fifty patients (69 males, 81 females), aged 3-70 years, with vitiligo were treated twice weekly with NBUVB. The starting dose was 250 mJ/cm2 in adults and 150 mJ/cm2 in children, with 20% dose increments at each subsequent visit given for a maximum period of 1 year and were followed-up for 6 months for stability of repigmentation. Statistical methods were employed to establish the relation between the response and the number of exposures, duration of treatment, cumulative dose and the compliance. Analysis of our study showed that a majority of our cases, about 73, achieved 25-75% repigmentation, with an average of 51+/-19 exposures, 51 had <25% repigmentation, with an average of 19+/-11 exposures and 26 had >75% repigmentation, with an average of 74+/-24 exposures. Good response to therapy was directly associated with good compliance, more number of exposures and increasing cumulative dose, which was statistically significant (P<0.01). Adverse effects were minimal. Only three patients developed depigmentation of repigmented sites during follow-up. Our study proves that NBUVB therapy is an effective and safe tool in the management of vitiligo, with good stability of repigmentation and cosmetic appearance.

Narrow‐band UVB for the treatment of vitiligo: an emerging effective and well‐tolerated therapy

Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1% of the general population. Photochemotherapy is the most commonly used treatment modality in extensive vitiligo, but is associated with many short- and long-term side-effects. Recently, narrow-band ultraviolet B (NBUVB) therapy has been reported to be an effective and safe therapeutic option in patients with vitiligo. We studied the efficacy and safety of NBUVB (311 nm) therapy in Indian patients with generalized vitiligo. Fourteen patients (six males and eight females), aged 12-56 years, with generalized vitiligo, were treated thrice weekly with NBUVB radiation therapy for a maximum period of 1 year. At the end of 1 year, 10 patients (71.4%) had marked to complete repigmentation and two each (14.3%) had moderate or mild repigmentation. Repigmentation sites showed an excellent color match. The response to therapy was correlated with the sites of involvement, duration of disease, and compliance to therapy. Adverse events were limited and transient. NBUVB therapy is effective and safe in Indian patients with vitiligo. Long-term follow up is required, however, to establish the stability of repigmentation.